Other
Cysticercosis
8
Pipeline Programs↗
3
Active Trials↗
4
Companies Involved↗
Cysticercosis is an early-stage landscape with 8 programs across 4 companies. The most active players are Bayer, Dexcel Pharma Technologies Ltd., GSK. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 21
Phase 34
Approved
No programs
Analysis
Trial Status
12
clinical trials
Completed7 · 58%
Not yet recruiting2 · 17%
Withdrawn1 · 8%
Terminated1 · 8%
Recruiting1 · 8%
Clinical Trials
Trial Activity
12 trials
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001205·500 enrolled
Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT
Completed·—·Phase 3·NCT02243644·97 enrolled
A Pilot Study of Neurocysticercosis Treatment
Completed·—·Phase 3·NCT00283699·178 enrolled
Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00290823·110 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)